[{"id":"f552d352-cef2-4502-8c92-07a6c652a075","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512718","created_at":"2021-01-18T12:08:19.999Z","updated_at":"2024-07-02T16:35:03.732Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT02512718","lead_sponsor":"Alexandra N. Carey","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 05/18/2023","primary_completion_date":" 05/18/2023","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2024-05-14"},{"id":"b016c854-a00e-4bf8-8d82-75c1a30954b9","acronym":"NF1NAC","url":"https://clinicaltrials.gov/study/NCT04481035","created_at":"2021-01-18T21:31:28.169Z","updated_at":"2024-07-02T16:35:14.069Z","phase":"Phase 2","brief_title":"Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1","source_id_and_acronym":"NCT04481035 - NF1NAC","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 06/14/2020","primary_completion_date":" 06/14/2020","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-19"},{"id":"7eb7e662-eaed-4643-b83d-3d968c7c14d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983238","created_at":"2021-07-30T17:54:56.973Z","updated_at":"2024-07-02T16:35:24.411Z","phase":"Phase 1/2","brief_title":"Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985","source_id_and_acronym":"NCT04983238","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 01/10/2022","start_date":" 01/10/2022","primary_txt":" Primary completion: 04/19/2023","primary_completion_date":" 04/19/2023","study_txt":" Completion: 06/26/2023","study_completion_date":" 06/26/2023","last_update_posted":"2024-01-05"},{"id":"665e399d-79d8-43cd-99aa-27cce90d5bc8","acronym":"DoDNAC","url":"https://clinicaltrials.gov/study/NCT04481048","created_at":"2021-01-18T21:31:28.500Z","updated_at":"2024-07-02T16:35:43.335Z","phase":"Phase 2","brief_title":"Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1","source_id_and_acronym":"NCT04481048 - DoDNAC","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-12"},{"id":"b5d2f702-d5fc-4365-82d2-f7ae513af4f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03413761","created_at":"2021-01-18T16:50:30.463Z","updated_at":"2024-07-02T16:36:05.898Z","phase":"","brief_title":"Antioxidant Supplements, Genetics and Chemotherapy Outcomes","source_id_and_acronym":"NCT03413761","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"],"overall_status":"Completed","enrollment":" Enrollment 1771","initiation":"Initiation: 12/18/2004","start_date":" 12/18/2004","primary_txt":" Primary completion: 11/12/2013","primary_completion_date":" 11/12/2013","study_txt":" Completion: 11/12/2013","study_completion_date":" 11/12/2013","last_update_posted":"2022-08-08"},{"id":"a4052baa-f418-48f0-bc38-3c3c3e89a2e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03625635","created_at":"2022-06-12T16:56:41.706Z","updated_at":"2024-07-02T16:37:07.989Z","phase":"","brief_title":"Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment","source_id_and_acronym":"NCT03625635","lead_sponsor":"Humberto Francisco Astiazaran Garcia, PhD","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL1A • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL1A • IL1B"],"overall_status":"Unknown status","enrollment":" Enrollment 34","initiation":"Initiation: 09/14/2015","start_date":" 09/14/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2018-08-10"},{"id":"597d2679-81ea-4390-ac43-951784196703","acronym":"EMPIRE","url":"https://clinicaltrials.gov/study/NCT02231203","created_at":"2021-01-18T10:28:02.890Z","updated_at":"2024-07-02T16:37:08.473Z","phase":"Phase 4","brief_title":"Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function","source_id_and_acronym":"NCT02231203 - EMPIRE","lead_sponsor":"Medical Center Alkmaar","biomarkers":" IL6 • TNFA • IL10","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2018-07-31"}]